A pilot study was conducted using a simulated epidural test dose to ascertain the effects adrenaline, adrenaline/ clonidine mixture, and clonidine alone on the accepted criteria for determining the occurrence of an epidural intravascular injection. Seventy-five ASA 1 or 2 children aged from six months to twelve years were sequentially allocated to one of three groups: group A: adrenaline 0.5 µg/kg, group AC: adrenaline 0.5 µg/kg and clonidine 0.3 µg/kg, and group C: clonidine 0.3 µg/kg. Effects on heart rate, T-wave amplitude and systolic blood pressure were determined after induction of anaesthesia and stabilization using sevoflurane in nitrous oxide and oxygen. Heart rate varied from baseline in a biphasic manner. The maximal increase in mean heart rate for all groups was <10 beats per minute (bpm). A heart rate rise of >10 bpm was not seen at any time in 54% of groups P=0.003). T-wave changes were also biphasic. 50% of groups A and AC had no increase in T-wave size of >25% at any sample point, compared with 96% in group C (Chi square=49.4, P<0.0001). 34% of groups A and AC did not have a change in systolic blood pressure of >15 mmHg during the study compared with 100% of group C (Chi-square=30.2, P<0.0001 ). There were no significant differences between groups A and AC for any parameter. Negative predictive value estimates for the current criteria for intravascular injection were low. Clonidine 0.3 µg/kg produced no effects on the study variables.
Regional analgesic techniques, particularly caudal epidurals, are commonly utilized in paediatric anaesthetic practice. Most neuraxial blocks are performed whilst the child is already anaesthetized. Local anaesthetic toxicity, whether manifested as convulsions or cardiac arrest, can present without warning and may be very difficult to treat effectively [1] [2] [3] [4] [5] [6] . Intravascular injection may occur due to unrecognised intravenous or subperiosteal placement of the needle or catheter, or the catheter may migrate into a vessel during epidural therapy. In the paediatric population intravascular injection has been estimated to occur in 0.4%-5.6% of epidural injections [7] [8] .
Evaluation of the efficacy of epidural test doses in children commenced in 1990 9 , and there have been many papers published since then including a recent review 10 . The criteria for defining a positive response to a test dose have been subject to revision [11] [12] [13] [14] [15] , but current recommendations are heart rate changes of >10 beats per minute, systolic blood pressure rises of >15 mmHg, and T-wave amplitude changes of >25% 10 .
Clonidine, an alpha-2 adrenoceptor agonist used as an additive to local anaesthesia, has been shown to significantly improve both the quality and the duration of analgesia provided by caudal local anaesthetic [16] [17] [18] . Clonidine can also have significant haemodynamic effects at the doses utilized in caudal anaesthesia, which may include hypotension and bradycardia [19] [20] .
Most studies on markers of accidental intravenous injection have used a test dose containing 0.5 µg/kg of adrenaline. This was supported by a dose-finding study performed by Tanaka and Nishikawa in which 0.5 µg/kg produced the desired changes in 100% of subjects 21 . This also corresponds to one fifth (0.1 ml/kg) of the dose for sacral anaesthesia (0.5 ml/kg), according to the Armitage Formula, using 0.25% bupivacaine with adrenaline 1 in 200,000 (5 µg/ml). The effect of clonidine on changes resulting from test doses has not been studied, apart from its use as an oral premedicant, where it was found to have no effect on the sensitivity or specificity of either isoprenaline or adrenaline for detecting changes in heart rate 22 .
The literature has changed over time, but T-wave changes are usually attributed to adrenaline, despite the fact that most of the data is derived from studies utilizing both lignocaine and adrenaline. The mechanism by which adrenaline might produce these changes is unknown. Despite the alleged frequency of intravascular injection, the paediatric anaesthetists at the authors' institution have rarely noted any T-wave changes.
We designed a prospective, observational study to describe the changes in heart rate (HR), systolic blood pressure (SBP), and T-wave morphology resulting from a standardized, intravenous adrenaline test dose, and then to compare the changes in these parameters when either an adrenaline/clonidine mixture or clonidine alone is injected. The intravenous test doses contained no local anaesthetic. We also attempted to conduct the tests simulating as closely as possible the usual clinical setting in which these blocks are performed.
MATERIALS AND METHODS
Approval for the study was obtained from the Hunter Area Research Ethics Committee. Informed parental consent was obtained for each participant. Seventy-five ASA 1 or 2 status children aged 0.5 to 12 years, undergoing minor elective surgery were recruited prospectively. Standard fasting guidelines were adhered to. Each child underwent preanaesthetic assessment by one of the researchers. The study was designed as a pilot study since no data exists on the effects of clonidine, and therefore we used sequential allocation rather than randomisation. Patients were sequentially assigned in an unblinded fashion to an adrenaline-only group (n=25) [group A], an adrenaline/clonidine group (n=25) [group AC], and a clonidine only group (n=25) [group C]. Allocation was strictly sequential, and there was no selection according to any other criterion.
Premedication of oral midazolam 0.5 mg/kg combined with paracetamol given thirty minutes preoperatively was used at the discretion of the anaesthetist. Anaesthesia was induced with sevoflurane and 60% nitrous oxide in oxygen. Sevoflurane was commenced at 2%, and increased by 2% each few breaths until unconsciousness was achieved. Intravenous access was then obtained. Once an appro-priate level of anaesthesia had been attained the airway was secured by insertion of a Laryngeal Mask Airway. Spontaneous ventilation was maintained in all cases. For children weighing less then 30 kg, an Ayres T-piece circuit with Jackson Rees modification was used with fresh gas flows appropriate to prevent rebreathing, whilst for children greater then 30 kg, a semi-closed circle system with gas flows of 3 litres per minute was used. Monitoring included: ECG lead II, pulse oximetry, automated non-invasive blood pressure (NIBP), and end-tidal gas analysis including CO 2 , O 2 , N 2 O, and sevoflurane (SpaceLabs Inc, Redmond, Washington, U.S.A.).
Anaesthesia was stabilized at an end-tidal sevoflurane concentration of 2.5% in 60% N 2 O/O 2 . The ECG was recorded and analysed as follows: The high level output from the "SpaceLabs" ECG module (model 90470-21, SpaceLabs Inc, Redmond, Washington, U.S.A.) was connected to a "PowerLab" model 8sp analogue-to-digital conversion and datalogging system (ADI Instruments, Castle Hill, N.S.W., Australia) interfaced with an Apple-Macintosh G3 computer (Apple Computer, Cupertino, California, U.S.A.). The high level ECG output signal was recorded to disc with a sample frequency of 1 kHz. All analysis was performed off-line with the aid of the PowerLab software.
Two minutes of baseline data including continuous ECG, NIBP at one-minute intervals; beat count and R-R variability were measured initially. Each patient then received a test dose injected via a peripheral venous cannula to simulate the intravascular administration of an epidural test dose. The volume of the injectate was standardized at 0.5 ml/kg for all patients to allow sufficient volume to standardize injection time. All injections were given over a period of 15 seconds. Group A received adrenaline 0.5 µg/kg, group AC received adrenaline 0.5 µg/kg and clonidine 0.3 µg/kg, and group C received clonidine 0.3 µg/kg. Data was recorded for a period of three minutes from the start of the injection. All measurements were performed prior to any surgical or other stimulation. Off-line analysis included measurement of the following variables: heart rate and T-wave amplitude changes from baseline at fifteen-second intervals, and systolic and diastolic blood pressure at one-minute intervals.
Data were entered into a spreadsheet (Microsoft Excel 97) and then analysed with the aid of a statistics package (Statview, Abacus Inc). Between-group comparisons were made using unpaired t-tests for population data and Chi squared tests or the Kruskal-Wallis test where appropriate.
RESULTS
Twenty-five patients were recruited to each of the three study groups. All suitable patients were invited to participate in the study, and all consenting patients were included in the study. The groups were recruited sequentially, A then AC then C.
Unless otherwise indicated, all results are reported as mean±standard deviation (SD). The groups were comparable in terms of age and weight (Table  1) . Baseline values for heart rate, SBP and T-wave amplitude are presented in Table 1 .
There were no significant differences between the groups, apart from the baseline T-wave amplitude. Three children in group A, three in group AC and seven in group C received oral midazolam premedication.
Changes in heart rate (HR) varied from baseline in a biphasic manner as shown in Figure 1 . Figure 1b shows the combined groups A and AC compared with group C.
The maximal increase in mean HR in the two adrenaline-containing groups was seen 30 seconds after commencing the injection, and was 7 beats per minute (bpm) (SD 10) in group A and 7 bpm (SD 5) in group AC. The maximum change in mean HR seen in group C was 2 bpm at 180 seconds (SD 4). The mean±one SD for group C included zero at all points.
A heart rate increase of >10 bpm was not seen at any time during the study in twenty-seven patients (54%) in the two adrenaline-containing groups, twelve in group A and fifteen in group AC. In twentythree (92%) patients in group C the HR did not increase >10 bpm. This difference was statistically significant (Chi square=11.4, P=0.003). There were no statistically significant differences between the adrenaline-containing groups.
The maximum decreases in mean HR were 8 bpm (SD 8) in group A and 6 bpm (SD 9) in group AC, both at 105 seconds post commencement of injection. In group C the maximum decrease in mean HR was 1 bpm (SD 2) at 45 seconds.
Fourteen patients in groups A (5) and AC (9) (28%), and 21 in group C (84%) had no heart rate change in either direction of >10 bpm at any sample point during the study (Chi square=22.3, P=<0.0001). There were no statistically significant differences between the adrenaline-containing groups.
The median duration of the heart rate rises >10 bpm was one fifteen-second interval in group A with an interquartile range (IQR) of one fifteensecond interval, and 1.5 intervals in group AC (IQR 1), and 1 interval (IQR 0.75) in group C. The median duration of a change of >10 bpm in either direction was 1.5 fifteen-second intervals for group A, 2 intervals for group AC, and 1 interval in group C, with IQRs of 3, 4 and 0.5 intervals respectively. There were no statistically significant differences between the groups. HR data are summarized in Table 2 .
Intravenous injection of adrenaline-or adrenaline/ clonidine-containing test doses did cause increases in mean systolic blood pressure (SBP). SBP data are summarized in Table 3 and shown graphically in Figure 2 .
Data collection was incomplete in groups A and AC as indicated in Table 3 . Figure 2b shows groups A and AC combined compared with group C.
Maximal change was at one minute for both groups. For group A this was 16 mmHg (SD 10), and for group AC this was 15 mmHg (SD 9). In group C there was no rise in mean SBP, and the maximum change seen was a fall of 2 mmHg from mean control SBP at the three-minute measurement. Seventeen children in groups A (10) and AC (7) (34%) did not have a change in SBP of >15 mmHg at any sample point during the study. There was a statistically significant difference between the three groups (Chi-square=30.2, P<0.0001), but no statistically significant differences between the adrenaline-containing groups.
There were some technical problems with the collection of T-wave data. In group A there were two patients who experienced short periods of junctional rhythm during which the morphology of the whole ECG complex was changed. Because of this, T-wave amplitude was not included in the analysis for changes at 60 seconds in two patients, and also at 75 seconds in one of these. A similar change occurred in one patient from group AC for readings between 60 seconds and 120 seconds. In addition, in a further two patients in group AC there was baseline instability which precluded accurate analysis, and no T-wave data from these patients was included in the analysis.
The mean control T-wave amplitude across the whole study was 0.45 mV (SD 0.25). There were also significant differences between the groups in the control T-wave amplitude (see Table1) .
T-wave amplitude changes did occur in groups A and AC. These are shown in Figure 3 . In these two groups, maximal increases in T-wave amplitude were observed 15 seconds after completion of the injection.
When compared according to group, the change in group A was 8.3% (SD 46) and in group AC 18% (SD 78). If groups A and AC were combined, the maximum change was seen at the thirty-second point where a rise of 13% (SD 63) was seen. Maximal changes in any direction occurred at 60 seconds in groups A and AC, where T-wave amplitudes were reduced by 25% (SD 35) and 31%(SD 55) respectively. In the combined groups A and AC the maximal change was -28% (SD 46) at the same point. In group C, the largest change seen was a decrease of 5%(SD 9) at 60 seconds. Mean ±1 SD for group C included zero % change at all points. These results are shown in Figures 4 and 4b . Four children (8%) from groups A (two children) and AC (two children) had no T-wave changes of >25% in either direction at any sample point during the study. Twenty-four children from these groups (50%) had no increase in T-wave size of >25% at any sample point, fourteen from group A and ten from group AC. In group C, 23 children had no change of >25% in either direction (92%), and 24 (96%) had no increase of >25%. These differences were highly significant (Chi-square=49.4, P<0.0001 and Chi square=16, P=0.003). There were no significant differences between groups A and AC.
T-wave amplitude increases were continuously visible for a median of one fifteen-second interval (IQR 1.5 intervals) in group A and two intervals (IQR 1.25) in group AC.
T-wave data are summarized in Table 4 . Three patients from groups A and AC were not positive at any sample point for any of the recommended criteria, and 15 were only positive for one. Eighteen patients from group C were not positive at any sample point for any criterion, and no patient was positive for more than one criterion.
Given that the effect of clonidine on the study parameters was so small, it could be regarded as inactive on the measured parameters, allowing us to estimate the sensitivity and specificity of each criterion. The values calculated are for the combination of groups A and AC, and assume group C to be a placebo group. These estimates are presented in Table 5 .
DISCUSSION
The main findings of our pilot study were as follows.
First, there is a biphasic change in heart rate seen with injection of both adrenaline and adrenaline/ clonidine, with a rise in heart rate peaking at 30 seconds followed by a fall peaking at 105 seconds. No changes were seen with clonidine alone.
Second, the size of the rise in heart rate is very small. The maximum increase seen at this point was 25 beats per minute for adrenaline alone and 16 for the adrenaline/clonidine mixture, with means of only 7 and 6 bpm. The duration of changes is also very short, with a median value of <2x15 second intervals for heart rate rises of >10 bpm in the two adrenalinecontaining groups. Fifty-four per cent of patients in groups A and AC fail to meet the suggested diagnostic criterion for a positive response at any sample point during the study.
Third, there was a small rise in systolic blood pressure in both groups containing adrenaline, which was maximal at the first blood pressure reading at one minute. There was no BP rise in the clonidine-alone group. Thirty-four per cent of patients from groups A and AC failed to meet the suggested diagnostic criterion for a positive response at any sample point during the study.
Finally, changes in T-wave amplitude did occur in both adrenaline-containing groups.
These changes were biphasic in nature, with a rise maximal at the 30-second point followed by a more sustained fall in amplitude peaking at the 60-second point. Any increases in amplitude were only shortlived. No changes were seen in group C.
Although the changes appear large if expressed as a percentage change from control, the actual magnitude of such changes on the monitor is very small. Similarly, given that the mean control heart rate was 102 beats per minute in the groups A and AC, then 367 the number of complexes in which these changes may be observed is quite small. There were also a significant number of patients in whom the T-wave size decreased or both increased and decreased. The most recent suggestions of criteria for a positive response to test doses are HR changes 10 bpm, SBP rise of 15 mmHg, and T-wave amplitude changes of 25% 10 . There has been a progressive reduction in the criteria for a significant increase in heart rate, and a debate about the requirement for atropine premedication to enable such changes to be detected. The ability of anaesthetists in the clinical environment to detect such changes has not been tested.
The heart rate changes, when they occur, are small and brief. Similarly, the T-wave changes found in our patients represent on-screen changes of only 0.3-1.4 mm if the monitor is set on 1 cm/mV, the standard setting for monitoring for ST/T wave changes. Many of these would be very difficult to appreciate on a moving trace with no baseline and rapid heart rates. The systolic blood pressure changes are difficult to measure and probably require continuous sampling to catch the peak effects. Our data suggest that the latest criteria are not reliable in the clinical setting. Further tightening of the criteria may also make them unlikely to be detected in the usual setting in which these blocks are performed.
Haemodynamic control in children is a balance between parasympathetic and sympathetic nervous systems 23, 24 . Pre-treatment with atropine has been suggested to improve both the ß-adrenergic receptor activity and baroreceptor responsiveness to sympathetic stimulation. This has been validated in several studies showing improved efficacy of test doses when applying HR criteria after atropine. Our study could be criticized on the basis that our patients did not receive atropine. We chose not to use it because, for sevoflurane, the use of atropine does not increase the sensitivity of haemodynamic changes as markers of intravascular injection 12 , although it may be more important for isoflurane and particularly for halothane. In addition, most paediatric anaesthetists no longer routinely employ atropine, particularly when not using halothane. Atropine pretreatment may not be relevant to the usual clinical setting in which blocks are performed [25] [26] [27] .
Our study suggests that a rise of 10 beats per minute is not a sensitive test after 0.5 µg/kg of adrenaline. Fifty-four per cent of our patients in the adrenaline containing groups failed to meet the increase >10 bpm criterion. Small reductions in the size of effect required would increase the sensitivity, but also decrease specificity and involve changes which would be impractical to detect in routine clinical practice.
Our findings on heart rate are in contrast to three published studies over the last three years 11, 14, 15 . Two of these 11, 14 included atropine pretreatment, and the third compared a sevoflurane group and a halothane group. Our figure of 46% for the sensitivity of adrenaline as an indicator based on heart rate rise is less than the 71% found by Kozek-Langenecker 15 and Desparmet 9 and much less than the 100% figure reported by Tanaka 14 . Possible explanations for this include the use of atropine pretreatment and a test dose containing local anaesthetic by both Tanaka and Desparmet. The importance of the lignocaine is not clear. In addition, Desparmet was using halothane rather than sevoflurane. Other factors possibly of importance include the speed of injection, which was faster in Tanaka's studies (five seconds compared to our 15 seconds), and not stated by Kozek-Langenecker, which may have resulted in higher peak levels of adrenaline. It is also possible that there may be an age effect, as our patients were older than the groups in one of Tanaka's studies 14 as well as that of Kozek-Langenecker, although our results did not suggest such a trend. Our study did not use routine premedication or controlled ventilation (as did other studies) as we wished to reflect our usual clinical practice. These differences in methodology may have contributed to our results differing from previous studies.
We did demonstrate T-wave changes as a result of adrenaline injection. The addition of clonidine appeared to exaggerate the effect although this failed to reach statistical significance. As discussed above, the clinical significance of these changes is uncertain, as the changes are small (<2 mm) and transient (often <30 seconds). Without software designed to measure T-wave size continuously, we contend that the interpretation of this sign is very difficult, particularly when focusing on performing other tasks involved in the performance of regional anaesthesia.
Kozek-Langenecker et al 15 studied simulated test doses of adrenaline 0.5 µg/kg without the use of atropine, and reported a sensitivity and specificity of 100% for T-wave amplitude changes of greater then 25% in either direction. In our study 8% of children receiving adrenaline failed to meet this criteria and 32% had changes of duration <30 seconds. The reason for this difference is not clear. The method used to record the ECG signal is not specified in this paper. Possibly the frequency at which the signal was recorded was not adequate to truly reproduce the T-wave changes. This was not the case in our study. The smaller sample size of 21 may also be of relevance. It is worth noting that this paper differs from those by most other authors in that T-wave amplitude changes in either direction are accepted as positive, rather than the more usual definition of only positive changes. This may be wise given that any changes occurring may be biphasic in nature, and our study supports this, in that the sensitivity of the technique rose from 52% to 92% if changes in both directions rather than only increases were accepted as positive.
Both our study and that of Kozek-Langenecker 15 differed from most others in the use of a test dose containing adrenaline alone. The aetiology of the T-wave changes reported is unknown. Fisher 7 has suggested, based on animal data, that it was most likely that the T-wave changes seen after injection of adrenaline and bupivacaine are due to the bupivacaine. He also described heart rate slowing and increased blood pressure in some patients and thought that these changes were due to adrenaline or reflex responses to adrenaline induced changes. More recently, all changes have been attributed to the ß-adrenergic effects of adrenaline, despite lignocaine being combined with the adrenaline. This assumption has recently been questioned by Tanaka 28 . Differences in premedication and ventilation strategy may also confound comparison of the studies of T-wave changes.
Other studies have consistently found changes in blood pressure similar to our data, although our sensitivity of 66% was less than that reported by other authors studying children anaesthetized with sevoflurane (Kozek-Langenecker 15 95% and Tanaka 14 81%). Once again the use of local anaesthetic in the test dose, the speed of injection, the use of atropine premedication and age differences may be of relevance.
The peak of the changes induced by the test dose may occur within the first minute after injection. This presents a considerable practical problem to most paediatric anaesthetists who routinely employ noninvasive blood pressure monitoring. Not only is this not a continuous method of measurement, but there is also the possibility of artefact and error affecting the outcome. It is possible that continuous blood pressure monitoring would improve the sensitivity of this test. Our study also showed that the addition of clonidine did not have a clinical or statistically significant effect.
Our results may be of some relevance to the use of ropivacaine in paediatric practice. Although ropivacaine has been suggested as the local anaesthetic of choice for paediatric regional anaesthesia because of its high therapeutic index 29, 30 , adrenaline is not recommended with ropivacaine, hence a separate test dose containing solution would be required. We acknowledge that at times dramatic ST segment changes may occur during regional anaesthesia that, if detected, might prevent an intravenous injection. However the role of adrenaline in producing such changes is unclear, and our results suggest that adrenaline cannot be relied upon to produce detectable changes. Further research is required to ascertain if the addition of an adrenaline-containing test dose can improve the safety margin compared to a slow incremental injection of one of the new local anaesthetic agents.
In conclusion, our study has shown that intravenous injection of adrenaline 0.5 µg/kg without local anaesthetic given as a 0.5 ml/kg injection over fifteen seconds in children anaesthetized with sevoflurane does not reliably produce either tachycardia or increased T-wave amplitude that is detectable in the clinical setting. If heart rate and T-wave changes in either the positive or negative direction are included, the sensitivity is increased, but not to a clinically adequate extent. Rises in systolic blood pressure were more reliable but still miss more than a third of adrenaline injections. The changes seen were small and transient. The addition of clonidine 0.3 µg/kg to the adrenaline did not produce significant changes in heart rate, T-wave amplitude or systolic blood pressure compared to the effects of adrenaline alone. The current criteria for a positive test dose were found to have poor negative predictive values. Clonidine alone produced no changes in heart rate, SBP or T-wave amplitude.
